Valneva says European Commission to terminate purchase agreement for its VLA2001 COVID candidate

FILE PHOTO: The logo of French-Austrian biotech firm Valneva is seen outside their headquarters in Vienna, Austria, December 16, 2021. REUTERS/Lisi Niesner/File Photo

(Reuters) – Valneva said on Monday it had received a notice of intent from the European Commission (EC) to terminate the advance purchase agreement for its VLA2001 COVID-19 candidate vaccine.

“The EC decision is regrettable especially as we continue to receive messages from Europeans who are looking for a more traditional vaccine solution,” Valneva Chief Executive Officer Thomas Lingelbach said in a statement.

The French drugmaker will work with the European Commission to agree to a remediation plan and to make VLA2001 available to those member states who still wish to receive it.

Source: Read Full Article